
    
      The study will be a double blinded, randomized controlled trial. The medications will be
      administered orally. The sample size will be 40 participants, 20 in the treatment group and
      20 in the control group. The study period will be 4 weeks. Eligible participants will have
      major depression by history for at least 8 weeks, between 18-65 years old, and in generally
      good health other than depression. The MADRS questionaire will be utilized to determine the
      response to the medications.
    
  